|
2011 MEETING SUMMARY |
 The
Alzheimer’s Drug Discovery Foundation (ADDF) held its 5th
Drug Discovery for Neurodegeneration: An Intensive Course on
Translating Research into Drugs in San Diego, CA on February
6-8, 2011. This annual didactic conference is focused on
training scientists on the process of translating research
findings into treatments for neurodegenerative diseases.
Approximately 145 scientists from academia, industry and
goverment, across career levels and disciplines, attended. In
addition, to foster the growth of the next generation of drug
discovery researchers, the ADDF awarded 26 scholarships to young
investigator to attend the conference and present posters of
their research.
The
conference commenced with plenary speaker, Berislav Zlokovic
from Rochester University, who spoke about the biology of the
blood-brain barrier with relevance to central nervous system
drug discovery. Sessions of the conference focused on
medicinal chemistry for biologists, early phases of drug
discovery – from high throughput screening through lead
optimization to pre-clinical proof of concept, and preparing the
scientific and regulatory requirements for clinical trials. The
conference also covered pertinent issues related to technology
transfer and working with industry partners as well as
real-world case studies across the neurodegenerative disease
spectrum (Alzheimer’s disease, Parkinson’s disease, ALS and
Multiple Sclerosis).
The conference also included
ample time for networking for investigators to exchange ideas
and foster the future collaborations needed for successful drug
discovery programs. A full meeting summary and tutorial,
including a listing of the relevant resources presented in the
conference, will be posted on the conference website as will
video casts of the presentations.
This
meeting was made possible through the successful collaboration
among government, industry and multiple disease foundations:
Cooperative Agreement 2U13AG031125 from the National Institute
on Aging and the National Institute of Neurological Disorders
and Stroke; Merck Research Laboratories; Biogen Idec; The
Michael J. Fox Foundation for Parkinson’s Research; Beyond
Batten Disease Foundation; JSW Life Sciences; Fast Forward LLC;
ALS Therapy Development Institute; and Novus Biologics. |
|
 |
|
COURSE
OBJECTIVES |
-
Train a cadre of interdisciplinary scientists in
the principles of drug discovery for neurodegenerative
disease;
-
Provide a platform to exchange ideas, knowledge and resources about drug discovery for
neurodegenerative disease;
-
Stimulate pre-clinical research in the discovery and testing
of novel compounds aimed at the prevention and treatment of
neurodegenerative disease; and
-
Build public-private partnerships that will accelerate
drug discovery for neurodegenerative disease.
|
|
SCIENTIFIC ADVISORY COMMITTEE |
|
Kurt R. Brunden, PhD,
University of Pennsylvania
Neil Buckholtz, PhD,
National Institute on Aging
Kathleen Denis, PhD,
The Rockefeller University
Howard Fillit, MD,
Alzheimer’s Drug Discovery Foundation
Brian Fiske, PhD,
Michael J. Fox Foundation for Parkinson’s
Research
William Matthew, PhD,
National Institute on Neurological Disorders
and Stroke
Lorenzo Refolo, PhD,
National Institute on Aging
Suzana Petanceska, PhD,
National Institute on Aging
Todd Sherer, PhD,
Michael J. Fox Foundation for Parkinson’s
Research
Diana Shineman, PhD,
Alzheimer’s Drug Discovery Foundation
Edward Spack, PhD,
Fast Forward, LLC
D. Martin Watterson, PhD,
Northwestern University |
|
|
|
TARGET
AUDIENCE |
-
 Academic and industry
scientists engaged in
drug discovery research
for neurodegenerative
disease or CNS
-
Business development
and licensing
professionals
-
Alliance management
professionals
-
Venture capitalists
and other investors
|
|
2007, 2008, 2008, 2009, 2010
PROGRAMS |
|
All pages will open in new windows:
|
|
WEBCASTS |
|
 The
2011 Drug Discovery for Neurodegeneration
Conference presentations are
available on
demand.
Click
here to view the 2011 videocasts and
here to view the 2010 ones.
|
|
